PAR 5.08% 28.0¢ paradigm biopharmaceuticals limited..

From Bell Potter's research note on 25/3:NEXT CATALYSTSThere are...

  1. 226 Posts.
    lightbulb Created with Sketch. 98
    From Bell Potter's research note on 25/3:
    NEXT CATALYSTS
    There are no significant changes to earnings and the company remains well funded to
    commence the US pivotal study.
    The upcoming meeting minutes from the pre IND meeting should provide further clarity on
    the volume of patients required for the pivotal study. This will be instructive for determining
    the extent of the company’s funding. Estimating the cost of a clinical trial is fraught with
    error, nevertheless at an estimated US$30K per patient for a 400 patient study the cost is
    US$12m (A$21m at current exchange rates). This cost is well and truly covered by our
    assumptions in the DCF valuation.
    We have previously raised the prospect of a second confirmatory pivotal study – potentially
    in Europe. Normally (but not always) new drugs require two phase III trials or approval.
    The DCF model includes an extensive allowance for clinical trials in knee osteoarthritis that
    should cover most of the cost of a second trial if required. At this time we do not anticipate
    a further capital raise will be required.
    The requirement for a further capital (if any) is dependent upon many variables may
    include the nature of the commentary from the FDA minutes and any future partnering
    transaction.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
28.0¢
Change
-0.015(5.08%)
Mkt cap ! $103.1M
Open High Low Value Volume
29.0¢ 29.0¢ 28.0¢ $68.26K 241.8K

Buyers (Bids)

No. Vol. Price($)
3 61682 28.0¢
 

Sellers (Offers)

Price($) Vol. No.
29.5¢ 24012 2
View Market Depth
Last trade - 10.11am 04/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.